San Diego, CA--January 19, 2010--Mentor Capital, Inc. (Pink Sheets:MNTR) has completed the set-up and initial funding of the Cancer Immunotherapy Index Fund. Through the CII Fund, Mentor Capital has now taken an initial equity position in each of the ten companies that make up Mentor Capital's proprietary Cancer Immunotherapy Index. The equally weighted CI Index was first created by Mentor Capital to track the growth of the cancer immunotherapy sector on an information basis. Since its formation in July 2009, the CI Index has appreciated at an approximate 100% annualized rate.


The Mentor Capital directed CII Fund invests in all ten companies in the CI Index. In an attempt to further increase return, Mentor Capital will begin to significantly overweight CI Fund investment into those CI Index companies that show the greatest medical and financial promise. Mentor Capital has authorization to raise approximately $130 Million in additional equity capital which is all slated for investment into the CII Fund.


The ten companies that Mentor Capital has invested in include Immunocellular Therapuetics, Ltd. (OTCBB:IMUC), Dendreon (NASDAQ:DNDN), Oncothyreon (NASDAQ:ONTY), Antigenics (NASDAQ:AGEN), Biovest International (BVTI.PK), Celldex Therapeutics (NASDAQ:CLDX), Northwest Biotherapeutics (OTCBB:NWBO), CEL - SCI Corp. (AMEX:CVM) and Generex Biotechnology (NASDAQ:GNBT) as a proxy for its wholly-owned immunotherapeutic subsidiary, Antigen Express, and Quantum Immunologics, Inc. a private company.

In cancer immunotherapy the patient's own immune system is trained to identify and attack cancer cells as the body normally does for any invading microbe. This approach avoids the severely negative effects of surgeries, chemotherapy and radiation.

Additional information on Mentor Capital plus listings and links to all Cancer Immunotherapy Index companies may be referenced from the company website: www.MentorCapital.com.

Forward Looking Statements, Safe Harbor and Risk Descriptions are Incorporated by Reference from the MNTR Company Web Site above.

__________

Chet Billingsley is the CEO and Chairman of Mentor Capital, Inc. Mentor Capital, Inc. invests in leading-edge cancer companies across all companies in its proprietary Cancer Immunotherapy Index and seeks to overweight acquisition or stock purchase funding in those companies with the greatest promise.


Chet Billingsley, CEO

Mentor Capital, Inc.
P.O. Box 1709
Ramona, CA 92065
(760) 788-4700
(760) 788-2525 Fax

 ↑ Back to Top